NASDAQ
RETA

Reata Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Reata Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$170.32
Today's High:
$172.05
Open Price:
$170.54
52W Low:
$21.83
52W High:
$172.05
Prev. Close:
$170.94
Volume:
1679766

Company Statistics

Market Cap.:
$6.51 billion
Book Value:
2.306
Revenue TTM:
$23.48 million
Operating Margin TTM:
-1455.15%
Gross Profit TTM:
$-167627000
Profit Margin:
0%
Return on Assets TTM:
-37.66%
Return on Equity TTM:
-112.39%

Company Profile

Reata Pharmaceuticals Inc had its IPO on 2016-05-26 under the ticker symbol RETA.

The company operates in the Healthcare sector and Biotechnology industry. Reata Pharmaceuticals Inc has a staff strength of 321 employees.

Stock update

Shares of Reata Pharmaceuticals Inc opened at $170.54 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $170.32 - $172.05, and closed at $171.98.

This is a +0.61% increase from the previous day's closing price.

A total volume of 1,679,766 shares were traded at the close of the day’s session.

In the last one week, shares of Reata Pharmaceuticals Inc have increased by +1.61%.

Reata Pharmaceuticals Inc's Key Ratios

Reata Pharmaceuticals Inc has a market cap of $6.51 billion, indicating a price to book ratio of 285.9438 and a price to sales ratio of 414.7289.

In the last 12-months Reata Pharmaceuticals Inc’s revenue was $23.48 million with a gross profit of $-167627000 and an EBITDA of $-340537984. The EBITDA ratio measures Reata Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Reata Pharmaceuticals Inc’s operating margin was -1455.15% while its return on assets stood at -37.66% with a return of equity of -112.39%.

In Q2, Reata Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 2885%.

Reata Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-2.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Reata Pharmaceuticals Inc’s profitability.

Reata Pharmaceuticals Inc stock is trading at a EV to sales ratio of 316.3418 and a EV to EBITDA ratio of -3.746. Its price to sales ratio in the trailing 12-months stood at 414.7289.

Reata Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$502.59 million
Total Liabilities
$125.09 million
Operating Cash Flow
$0
Capital Expenditure
$274000
Dividend Payout Ratio
0%

Reata Pharmaceuticals Inc ended 2024 with $502.59 million in total assets and $0 in total liabilities. Its intangible assets were valued at $502.59 million while shareholder equity stood at $87.29 million.

Reata Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $125.09 million in other current liabilities, 38000.00 in common stock, $-1490651000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.84 million and cash and short-term investments were $330.21 million. The company’s total short-term debt was $2,456,000 while long-term debt stood at $73.13 million.

Reata Pharmaceuticals Inc’s total current assets stands at $401.85 million while long-term investments were $0 and short-term investments were $281.37 million. Its net receivables were $22.66 million compared to accounts payable of $19.86 million and inventory worth $2.94 million.

In 2024, Reata Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $274000.

Comparatively, Reata Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$171.98
52-Week High
$172.05
52-Week Low
$21.83
Analyst Target Price
$172.45

Reata Pharmaceuticals Inc stock is currently trading at $171.98 per share. It touched a 52-week high of $172.05 and a 52-week low of $172.05. Analysts tracking the stock have a 12-month average target price of $172.45.

Its 50-day moving average was $146.77 and 200-day moving average was $89.02 The short ratio stood at 2.91 indicating a short percent outstanding of 0%.

Around 410.1% of the company’s stock are held by insiders while 8846.5% are held by institutions.

Frequently Asked Questions About Reata Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Reata Pharmaceuticals Inc is RETA

The IPO of Reata Pharmaceuticals Inc took place on 2016-05-26

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$2.3
0
0%
$8.82
-0.17
-1.89%
$49.33
-1.65
-3.24%
$217.9
-2.1
-0.95%
$8.02
0.15
+1.91%
$5.15
-0.15
-2.83%
$0.35
0.01
+2.09%
$38.23
0
0%
$59.16
-5.99
-9.19%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich’s ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Address

5320 Legacy Drive, Plano, TX, United States, 75024